BACKGROUND:
The development of new drugs, vaccines and diagnostics is complex, requiring many different skills. Each individual involved in a part of product R&D must be aware of the process overall and be able to relate their activities to it and to the needs of the other participating scientists and clinicians. Research scientists seek the discovery and confirmation of new knowledge by initiating or creating a hypothesis and then transforming it first into a theory and later into a new discovery. Product developers turn such discoveries into full-grown products which address public health needs through a long and quite different processes. Generally, research and development are two different disciplines. People working in these two areas do not think alike; they have different cultures. Often they work in isolation from each other, so they do not understand each other well. However, both disciplines are essential for the development of new drugs, vaccines and diagnostics. Furthermore, discovery of new knowledge is meaningless if it is not translated into new products that meet the needs of the public health. Currently, there are only few courses in the north that give a good overview of the entire drug discovery and development process such as post-graduate courses at University of Cardiff, ECPM at University of Basel, University of Lyon and may be a few others. In majority of countries around the world, most of the topics related to product R&D are scattered throughout the various university curricula, including basic science, organic chemistry, immunology, pharmacy, pharmacology, vaccinology and clinical pharmacology. However, everyone involved in research or development must know their responsibilities and able to relate their tasks to all the others which make up the process of product R&D. The objective of the proposed course is to pull together the various components needed for product R &D into a dedicated MSc-PhD course. Discussions between different universities who are interested in this project have taken place on several occasions. Recently, six universities in four countries (Japan, Thailand, China and Colombia) have started working together to draft the content of the curriculum.
The curriculum is designed to provide basic knowledge of the product R&D process. It aims to demonstrate that new product discovery and the various development activities such as chemistry, toxicology, clinical investigations and regulatory practices are related as a continuous process, and that one discipline cannot carry out the whole process on its own.
Format of the course:
This is a joint project involving a number of universities in different countries. During the first five weeks, all students will take a core course on product R&D aimed at giving them an overview of the process. It will be held on a rotational basis in one of the participating universities. During the next ten weeks, students will select for in-depth exploration an area of their special interest, for example drug discovery, toxicology or clinical, and for this period will work in an institution that offers that specific area.
For the last 8 months, students will be attached to a specific institution, pharmaceutical company or biotech to work on a particular project.
The first four months of the course will be mainly lectures and case studies. The remaining 8 months will be mainly practical, including laboratory studies or clinical practice. The course is modular to allow those who already work in the area of product R&D to attend the appropriate parts of the course. This would provide such personnel with the opportunity of reviewing and discussing the special problems they encountered in their routine, real world work.
At the end of five weeks, students will be awarded a diploma in product research and development from Nagasaki University.
At the end of the first year, the successful students may receive a MSc. (subject to university requirement). Progression to PhD will depend on the evaluation of their first year performance. Those chosen as PhD candidates will do their thesis in the area of interest in one of the companies with on -going activities. Each student will receive their degree from the university that they registered for the course.
Contents of the core diploma course
This part of the course will begin with a general overview of product R&D (drugs, vaccines and diagnostics), continue with a series of lectures on discovery research, transitioning between research and development, CMC (chemical, manufacturing and control) requirements, toxicology requirements from development to product license, pharmaceutical and analytical development, pharmacokinetics and metabolic studies, clinical studies -phase I-IV trial design and protocols -project planning and management, handling of safety data in development, regulatory requirements, post regulatory clinical studies, patents issues and other aspects of product development i.e. international standards of good practice, ethics in clinical research, DSMB (Data and safety Monitoring Boards), commercial and marketing activities, and public health implementation.
Contents of the course during the next ten weeks:
The students will focus on the area of their interest. They will attend seminars and lectures in specific area such as discovery, CMC, toxicology, vaccinology, pharmacology, clinical development and regulatory requirements. For this, the student can choose to attend at their registered university (if such course is running during the period) or at another affiliated institution.
The program of core course in product R&D (Syllabus)
Module 1: Course Orientation This module provides an over view of the need for a specific drug or vaccine for a disease or condition. The challenge for pharmaceutical research is to analyze a disease or condition to determine its effect on the body. This analysis leads to discovery of drug, vaccine or diagnostic which could then turn into a product. Resource requirements of current development paradigm and the time taken to develop a new product will be discussed. The following topics will be covered:
!Key medical and public health issues, and the need for new products !Discovery research and product development and the different approaches required for each of them !Resource implication for product development !Stakeholders in Product Research and Development !Major players Large, medium and small pharmaceutical companies Academic institutions CRO Biotechs Regulatory
Module 2: Drug Development !Discovery Research: A comprehensive review of various approaches for new drug discovery from early history of mankind to contemporary techniques such as rational drug design, medicinal chemistry, in silico technology, genomics, proteomics, and pharmacogenomics will be covered. Examples of therapeutic areas derived from these approaches will be provided including lessons learned, pitfalls, and evolution towards a newer and more efficient approach. The importance of having the patents protected in the early stage as well as the strategy to publish (or not publish) the novel findings will be discussed. The following topics will be covered: Historical Overview of modern drug discovery Drug Targets Lead Generation Lead Optimization Patents and publications !Chemical Development: Chemistry, manufacturing and control (CMC): The required standards for composition, manufacture process, and controls information of the drug substance and the drug product that can ensure proper identification, quality, purity and strength of the investigating product will be described. 
Module 3: Vaccine Development
Rational: World eradication of small pox clearly showed that vaccine is a powerful tool to control the disease. First of all, we will discuss about the reasons why some vaccine developments were successful whereas some were not. Then we will discuss what types of vaccine or vaccine development are ideal to control the major diseases such as infectious diseases, cancer, autoimmune diseases etc.
!Discovery Research -Vaccines
Vaccine effect is dependent on the acquired immunity that directed for the elimination of non-self including microorganisms, parasites, and cancer cells induced by the immunization of some appropriate antigens. What is the most effective acquired immunity against the disease? How do you select good antigens for such an effective vaccine development? And how do you make that antigen(s) more effective? We will see the most advanced knowledge and technology that will facilitate vaccine discovery research. A historical review and overview of modern vaccine discovery will be presented. Various methods for antigen screening such as bioinformatics, protein chemistry, recombinant antigens, high-throughput, cell free recombinant system will be discussed. The evaluation of candidate antigens and selection of candidates for development will be described. Alternatives to using antigens will be presented. Examples of antigens derived from these approaches will be provided including lessons learnt, pitfalls, and evolution towards a newer and more efficient approach. Different adjuvant will be explored and discussed. The importance of having the patents protected in the early stage as well as the strategy to publish the novel findings will be discussed. Soluble or suspension, Route, frequency, interval, number of dose, with or without adjuvant, mucosal immunization (aerosol, oral, nasal, inhalation, food), instability Quality assurance/quality control, Regulatory !Preclinical development Preclinical Safety and immunogenicity assessment for vaccine development is performed by using animal model. There are two major check points, one is injection sites and the other systemic effect such as hypersensitivity and autoimmunity. Overview of the preclinical research will be demonstrated by using several typical experiences for vaccine development. Methods for the safety assessment and immunogenicity will be demonstrated. There will be a special session to demonstrate the classical and novel concept of animal model. Safety assessment Toxicity test for animal: regional complications, systemic toxicity such as fever, anaphylactic shock, Immunogenicity assessment Animal model used in pre-clinical studies The use of humanized animal model !Clinical Development Clinical development of vaccine is somehow different from that of drug especially in the evaluation process and ethical aspects. The participants in vaccine trial are usually healthy volunteers and the sample size is normally greater than drug trial. It also takes longer duration to demonstrate the efficacy e.g. it needs a naturally infection to demonstrate the effect as challenging infection is not ethically acceptable. Administration of vaccine requires more complex procedures than drug trials, for example it requires cold chain, injection instruments, health workers, etc. The assessment of pre-clinical information to proceed to human will be emphasized. In the Clinical trial section, the various investigational phases of clinical research (Phases I-IV) will be demonstrated. Module 4: Diagnostic Development Diagnostic tools in combination with therapeutic or preventive medical care are important to develop for public health purpose. Without good diagnostic method, it would be impossible to evaluate the disease burden in the community, to treat the patients and to protect the society against the disease. Practical approach towards the development of really effective diagnostic tools for public health will be demonstrated and discussed. In the overview, several excellent examples will be shown. Discovery session will show three steps for the discovery, Necessity assessment, technology selection, prototype production. Evaluation of clinical applicability such as Sensitivity and specificity will be discussed. Detailed protocol for the Clinical development will be demonstrated.
Overview Discovery and Development of diagnostic tools Necessity assessment, Principles and technology selection, prototype production and assessment.
Identify 
Module 6: Clinical Data Management
Project planning and management at every stage of development will be described. Developmental objectives, crucial milestones, concise detailed analysis of product and roadmap to market will be demonstrated, including Patent process. Regulatory strategies and strategies for dealing with potential roadblocks and hurdles in the product development process will be discussed. The plan will include a lay out of an accurate and realistic budgets and timelines throughout the project development. A practical workshop on project planning and management will be included. Following topics will be covered:
Project 
Module 7: Activities after Registration
Objective: a. to identify stakeholders to be involved in post regulatory activities, their functions and roles in bringing the products to solve the intended public health problems. b. describe the policy instruments to bring the products to the intended beneficiaries. c. develop strategies for public and private partnership to encourage -Research and development in areas of need and -Advocate the public sector to allocate funds to allocate funds to bring products to the intended beneficiaries.
d. develop evidence based actionable message, identify resources requirement to scale up the products for use in the health care system (diagnostic tests, vaccines and drugs) as well as describe strategies to mobilize these resources.
e. describe mechanisms and strategies for post marketing product vigilance for product quality, post marketing efficacy and side effects.
f. Identify the human resource capacity strengthening needs and strategies to fulfil those needs such as through best practice health services research using "unqualified" personnel and training of the trainers.
!Stakeholders to be involved in making product development work for the intended beneficiaries Stakeholders in health care systems are important in making development products work for poor people and intended beneficiaries. These include the policy makers, the system managers, directors of facilities, the practitioners and the intended beneficiaries. Each of these stakeholders has unique responsibility, roles and functions. The roles and functions have to be coordinated to make the system make the products work. The unique roles, functions and the tools to coordinate the stakeholders to make the product work will be described with specific examples for HIV/TB care and addressing poverty gender based inequalities and how to deal with them. Specific stakeholders to be discussed in details are:
Public policy System policy Facility Policy Practice Policy Empowerment of public !Policy Instrument Social factors to a large extent shape the success for failure of bring innovative products to benefit the intended beneficiaries. Policy instruments are needed to deal with the complexity of social impediments to health and diseases. The use of the policy instruments will need the right understanding of diseases and their proximate and distant determinants. The right understanding can give insight to: a) targeting the products; b) development rules and regulation to procure and provide the products to the intended beneficiaries; c) allocation of resource to finance the purchase of the products to target beneficiaries and d) development of services either at the public or private sectors where appropriate. Specific instruments to be discussed in details are:
Public health need and vulnerable groups Targeting Rule regulation (financing, guidelines) Resources allocation Service planning: primary, secondary, tertiary care
!Public Private Partnership (3 hours)
The purpose of partnership between the public and private sector is to promote the interface between product development and their use in clinical and systems settings. Partnership can have an effect of the overall priorities and successes of product development. A good partnership will strengthen the credibility of the relationship between the public and private sector over the long term. There are several possible reasons to develop a public and private partnership. The most important one should be the need to achieve a task, which is not achievable if each of the partners works independently. Typically, these activities help control a 'neglected' disease or condition in developing countries such as through development or distribution of a drug, diagnostics, vaccines, contraceptive and other products. In general, there are two types of partnership: 1) those that want to tackle a problem in a more efficient way; and 2) those that are created to tackle what is conceived as intractable problems such as the development of a malaria vaccine. These partnerships want to find new ways of tackling the problems because the world does not yet know how to do it. Since the cost of product development can be high, economic consideration to promote an interface between development/clinical use and approval, post marketing must be in place. Both the "push" and "pull" mechanisms will be described. The "push" mechanism guide the research and development initiatives, while the "pull" mechanism ensure that the public sector will guarantee allocation of funds to purchase products for the intended beneficiaries once they are available. Public-private partnership Function and structure of partnerships Good characteristic of partnerships Monitoring partnerships Examples of partnerships for product research and development
!Improving the quality use of new products in health systems Evidence for efficacy and safety of the products must be interpreted for potential users of the products to enhance quality use for intended beneficiaries. The potential users include policy makers, practitioners, patients and public, including the media. The interpretations have to be transformed into evidence based actionable products relevant for each of potential users. Other strategies such as the "triangle that moves the mountain" and the "academic NGO" movement of the University of Ottawa can be used to develop strategies to link evidence based actionable message to potential users. Diagnosis -Characteristics of tests and resource needed to implement the test in health system. -Access to diagnostic services and case finding for poverty and gender-based inequalities -Balancing public protection and stigmatization and denial (TD/HIV) Vaccine: -Characteristics of Vaccine and resource needed to implement the test in health system. -Coverage and herd immunity -Post vaccination exposure and risk activities DRUG.
-Indications, contraindications, use and resource needed to implement the test in health system. -Compliance of provider -Compliance of subjects -Measures to improve compliance !Post marketing product vigilance New products, such as drugs, vaccines and diagnostic tests have both benefits and side effects, some of which might not be apparent until the products have been used over a long period of time. Therefore, a system must be developed to measure the benefits as well as risks. Benefits need to be weighed against the occurrence of adverse events. A risk/ benefit analysis of the products must be evaluated using standardized tools and procedures. The importance of guidance for standardization of terminology, data collection, verification and presentation of efficacy and adverse reaction reports will be emphasized and discussed. Possible topics include:
The definition of pharmacovigilance. The scope, instruments/tools, and processes needed for Pharmacovigilance of medicinal products for human use. Systems for standardization of pharmacovigilance reporting and exchange of pharmacovigilance information and subsequent appropriate actions. Administrative and legislative information relevant to medicinal products for human use. The mechanism for reviewing and updating legislative and technical areas for general use.
!Capacity for optimal delivery of new product: Training and Health services research It is important that countries have the capacity to identify, innovate and adapt new products to its own need and constraints in order to address their unique burden of illnesses including the burden of tropical diseases. At times, health service research might be carried out to document the possibility of using products via "unqualified personnel" through training to ensure best practice (such as the use of nurses for provide contraceptive services). Policy formulation, implementation and evaluation must be in place. Most developing countries do not have capacity to formulate policy identify, innovate and adapt new products to relevant to their problems. Vaccines against ROTA virus, which was not approved in the US due to rate intussusceptions might have be very beneficial in developing countries in preventing burden of illnesses from ROTA virus diarrhea over the incidence of complications because the incidence of ROTA virus diarrhea is high. Likewise, capacities for the development of treatment guidelines and their financing, and optimal facility planning for new products are needed to optimally distribute and use the new products for the intended beneficiaries. Individual practitioners also need skills to search for the best evidence about the use of products within the constraints of their health systems. Various models of international collaboration for capacity strengthening are available such as the Thai Golden Jubilee grant. The topics to be considered and discussed include:
Policy 
